Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Tarsus Pharmaceuticals (TARS) EBIAT (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of EBIAT data on record, last reported at -$8.4 million in Q4 2025.

  • For Q4 2025, EBIAT rose 63.77% year-over-year to -$8.4 million; the TTM value through Dec 2025 reached -$66.4 million, up 42.52%, while the annual FY2025 figure was -$66.4 million, 42.52% up from the prior year.
  • EBIAT reached -$8.4 million in Q4 2025 per TARS's latest filing, up from -$12.6 million in the prior quarter.
  • Across five years, EBIAT topped out at $10.4 million in Q1 2021 and bottomed at -$41.9 million in Q4 2023.
  • Average EBIAT over 5 years is -$19.7 million, with a median of -$21.4 million recorded in 2022.
  • Peak YoY movement for EBIAT: skyrocketed 630.2% in 2021, then plummeted 447.17% in 2023.
  • A 5-year view of EBIAT shows it stood at -$14.9 million in 2021, then grew by 8.43% to -$13.6 million in 2022, then plummeted by 208.13% to -$41.9 million in 2023, then surged by 44.84% to -$23.1 million in 2024, then soared by 63.77% to -$8.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$8.4 million in Q4 2025, -$12.6 million in Q3 2025, and -$20.3 million in Q2 2025.